What is the first line treatment for Myasthenia Gravis?

The first-line treatment for Myasthenia Gravis is the use of anticholinesterase drugs. These medications, such as pyridostigmine, work by inhibiting the enzyme acetylcholinesterase, which breaks down acetylcholine at the neuromuscular junction. By preventing the breakdown of acetylcholine, these drugs enhance neuromuscular transmission, leading to improved muscle strength and function in patients with Myasthenia Gravis.

Anticholinesterase drugs specifically target the underlying problem in Myasthenia Gravis, which is the autoimmune attack on acetylcholine receptors at the neuromuscular junction. Because they improve the communication between nerves and muscles, they provide significant symptomatic relief, making them the first-line choice for managing the condition.

Other treatment options, such as immunotherapy, may be used in more advanced or refractory cases, but anticholinesterase drugs remain the cornerstone of initial management. Treatments like antibiotics and physical therapy do not address the primary pathophysiology of Myasthenia Gravis and are not effective in alleviating the symptoms caused by this autoimmune disorder.